[go: up one dir, main page]

MX2023009910A - Vectores lentivirales dirigidos a los linfocitos. - Google Patents

Vectores lentivirales dirigidos a los linfocitos.

Info

Publication number
MX2023009910A
MX2023009910A MX2023009910A MX2023009910A MX2023009910A MX 2023009910 A MX2023009910 A MX 2023009910A MX 2023009910 A MX2023009910 A MX 2023009910A MX 2023009910 A MX2023009910 A MX 2023009910A MX 2023009910 A MX2023009910 A MX 2023009910A
Authority
MX
Mexico
Prior art keywords
lentiviral vectors
lymphocytes
vectors directed
methods
cell
Prior art date
Application number
MX2023009910A
Other languages
English (en)
Inventor
Molly R Perkins
Kevin M Friedman
Original Assignee
Kelonia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kelonia Therapeutics Inc filed Critical Kelonia Therapeutics Inc
Publication of MX2023009910A publication Critical patent/MX2023009910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan vectores lentivirales que comprenden una proteína de envoltura heteróloga y mutada, una proteína dirigida y al menos un transgén para el suministro a una célula caracterizada por la proteína dirigida y para la expresión por parte de esta célula. También se proporcionan métodos y materiales para producir los vectores lentivirales descritos en el presente documento, métodos para transducir células objetivo y células transducidas por vectores lentivirales de acuerdo con la presente descripción.
MX2023009910A 2021-02-26 2022-02-25 Vectores lentivirales dirigidos a los linfocitos. MX2023009910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163154639P 2021-02-26 2021-02-26
PCT/US2022/018027 WO2022183072A1 (en) 2021-02-26 2022-02-25 Lymphocyte targeted lentiviral vectors

Publications (1)

Publication Number Publication Date
MX2023009910A true MX2023009910A (es) 2023-11-09

Family

ID=80780729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009910A MX2023009910A (es) 2021-02-26 2022-02-25 Vectores lentivirales dirigidos a los linfocitos.

Country Status (11)

Country Link
US (3) US20240218390A1 (es)
EP (1) EP4298114A1 (es)
JP (1) JP2024507996A (es)
KR (1) KR20230160242A (es)
CN (1) CN117203223A (es)
AU (1) AU2022227021A1 (es)
BR (1) BR112023017213A2 (es)
CA (1) CA3212006A1 (es)
IL (1) IL305411A (es)
MX (1) MX2023009910A (es)
WO (1) WO2022183072A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4298114A1 (en) 2021-02-26 2024-01-03 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
WO2023114884A2 (en) 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
CN119895039A (zh) 2022-07-25 2025-04-25 因特尔乌斯生物治疗公司 突变多肽、包含所述突变多肽的组合物及其用途
AU2023342046A1 (en) * 2022-09-12 2025-03-27 The Board Of Trustees Of The Leland Stanford Junior University Composition and method of universal pseudotyped retroviruses
CN117802163A (zh) * 2022-09-30 2024-04-02 深圳市济因生物科技有限公司 靶向载体及其制备方法与用途
TW202434735A (zh) * 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
CN120457212A (zh) * 2022-11-04 2025-08-08 优莫佳生物制药股份有限公司 展示融合分子的慢病毒颗粒及其用途
WO2024145593A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retrovirus, compositions, and methods of use
WO2024145605A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retroviruses, compositions, and methods of use
WO2024145599A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retrovirus, compositions, and methods of use
WO2024145622A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retroviruses, compositions, and methods of use
EP4680753A2 (en) * 2023-03-17 2026-01-21 Kelonia Therapeutics, Inc. Dual targeted gene therapy
EP4689141A2 (en) * 2023-03-30 2026-02-11 Kelonia Therapeutics, Inc. In vivo lentivirus animal models
KR20250167052A (ko) * 2023-04-10 2025-11-28 선전 제노큐리 바이오테크 컴퍼니 리미티드 돌연변이형 vsvg 및 표적화 벡터
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024238153A1 (en) * 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
EP4484563B1 (en) * 2023-06-30 2025-11-05 EsoBiotec SA Viral vector and producer cell
WO2025011662A1 (zh) * 2023-07-12 2025-01-16 深圳市济因生物科技有限公司 一种载体和体外转染非激活t细胞的方法
WO2025021173A1 (zh) * 2023-07-25 2025-01-30 深圳市济因生物科技有限公司 一种病毒载体及tcr亚基的应用
WO2025036498A1 (zh) * 2023-08-16 2025-02-20 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN116987157B (zh) * 2023-09-27 2023-11-28 深圳华大生命科学研究院 一种弹状病毒包膜蛋白、含其的靶向慢病毒载体及其应用
WO2025149068A1 (zh) * 2024-01-10 2025-07-17 深圳市济因生物科技有限公司 一种病毒颗粒及其制备方法与应用
WO2025178803A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California Compositions and methods for targeted delivery of nucleic acid-binding effector polypeptides
WO2025203091A2 (en) * 2024-03-26 2025-10-02 Micro Crispr Pvt. Ltd. Surface modification of lentiviral particle and producer cell thereof
CN119174831A (zh) * 2024-11-26 2024-12-24 中国医学科学院医学实验动物研究所 基于冠状病毒Spike与hACE2互作介导的细胞特异性基因递送系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1171624B1 (en) 1999-04-29 2007-07-25 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE60041210D1 (de) 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
EP1581056B1 (en) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8008268B2 (en) 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
EP2019144A1 (en) 2007-07-23 2009-01-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vector particles for targeting CD34+ cells
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
CA2987102A1 (en) 2008-07-01 2010-01-07 Genocea Biosciences, Inc. Screening system
WO2012088381A2 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
ES2842102T3 (es) 2012-08-20 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
ES2761638T3 (es) 2014-01-10 2020-05-20 Sirion Biotech Gmbh Vectores lentivirales pseudotipados
CA2936352A1 (en) 2014-01-21 2015-07-30 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
AU2015210775B2 (en) 2014-01-30 2020-07-02 Children's Hospital Medical Center An improved fetal hemoglobin for genetic correction of sickle cell disease
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
PL3134095T3 (pl) 2014-04-25 2020-10-19 Bluebird Bio, Inc. Ulepszone sposoby produkcji komórek do adoptywnych terapii komórkowych
US9759689B2 (en) 2014-05-02 2017-09-12 The Regents Of The University Of Michigan Real-time detection and imaging of terahertz pulse radiation by using photoacoustic conversion
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
WO2019056015A2 (en) 2017-09-18 2019-03-21 Children's Hospital Medical Center STRONG ISOLATOR AND ITS USES IN GENE ADMINISTRATION
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
ES2991089T3 (es) 2017-09-22 2024-12-02 Centre Nat Rech Scient Glicoproteína mutada del virus de la estomatitis vesicular
CA3101510A1 (en) * 2018-06-01 2019-12-05 University Of Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
WO2020123936A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
EP3972988A1 (en) 2019-05-20 2022-03-30 Instituto de Biologia Experimental e Technologica (IBET) Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it
WO2020236263A1 (en) 2019-05-23 2020-11-26 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
EP4298114A1 (en) 2021-02-26 2024-01-03 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
EP4323381A1 (en) 2021-04-16 2024-02-21 Massachusetts Institute of Technology Viral targeting of hematopoietic stem cells
WO2023114884A2 (en) 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof

Also Published As

Publication number Publication date
EP4298114A1 (en) 2024-01-03
JP2024507996A (ja) 2024-02-21
BR112023017213A2 (pt) 2023-11-21
CA3212006A1 (en) 2022-09-01
KR20230160242A (ko) 2023-11-23
US20240218390A1 (en) 2024-07-04
US20240150788A1 (en) 2024-05-09
AU2022227021A1 (en) 2023-09-21
WO2022183072A1 (en) 2022-09-01
US12312593B2 (en) 2025-05-27
CN117203223A (zh) 2023-12-08
US20250277238A1 (en) 2025-09-04
IL305411A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2023009910A (es) Vectores lentivirales dirigidos a los linfocitos.
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
BR112021023353A2 (pt) Método de triagem de uma população de células, retrovírus, método de liberação de um ácido nucleico para uma célula, método para detectar uma interação entre um retrovírus e uma célula, biblioteca de retrovírus, e, população de células
CR20230303A (es) Composiciones y métodos para reducir el mhc de clase ii en una célula
MX2018007842A (es) Nueva generacion de tcr especificos de antigeno.
MX2023004505A (es) Polinucleotidos que contienen adn y guias para sistemas crispr de tipo v, y metodos de fabricacion y uso de los mismos.
MX2020004541A (es) Edicion de genes de celulas primarias.
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
MX2023011927A (es) Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
CO2023009612A2 (es) Composiciones y métodos para reducir los hla-a en una célula
PH12022550676A1 (en) Cells with sustained transgene expression
CL2024001577A1 (es) Composiciones y métodos para dirigirse específicamente a bcl11a
MX374756B (es) Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
MX2024001443A (es) Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
MX2025000419A (es) Metodos para expandir poblaciones de celulas t
CL2022002208A1 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación
MX2021010543A (es) Receptores de linfocitos t y metodos de uso de estos.
MX2023012217A (es) Direccionamiento viral de celulas madre hematopoyeticas.
WO2020232141A3 (en) Compositions and methods for treating t cell exhaustion
WO2023141106A3 (en) Recombinant cell line expressing membrane proteins and vesicles prepared therefrom
MX2022015788A (es) Metodos y composiciones para editar el sitio de b2m en celulas b.
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
MX2021010542A (es) Receptores de linfocitos t y metodos de uso de estos.
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa